132 related articles for article (PubMed ID: 19776461)
41. Cost-effectiveness analysis when the WTA is greater than the WTP.
Willan AR; O'Brien BJ; Leyva RA
Stat Med; 2001 Nov; 20(21):3251-9. PubMed ID: 11746316
[TBL] [Abstract][Full Text] [Related]
42. It's time to choose the study design!: net benefit analysis of alternative study designs to acquire information for evaluation of health technologies.
Shavit O; Leshno M; Goldberger A; Shmueli A; Hoffman A
Pharmacoeconomics; 2007; 25(11):903-11. PubMed ID: 17960950
[TBL] [Abstract][Full Text] [Related]
43. [Use of probabilistic methods in economic evaluation of health technologies].
Darbà J
Gac Sanit; 2006; 20(1):74-7. PubMed ID: 16539999
[TBL] [Abstract][Full Text] [Related]
44. Calculating and Interpreting ICERs and Net Benefit.
Paulden M
Pharmacoeconomics; 2020 Aug; 38(8):785-807. PubMed ID: 32390067
[TBL] [Abstract][Full Text] [Related]
45. A full Bayesian model to handle structural ones and missingness in economic evaluations from individual-level data.
Gabrio A; Mason AJ; Baio G
Stat Med; 2019 Apr; 38(8):1399-1420. PubMed ID: 30565727
[TBL] [Abstract][Full Text] [Related]
46. Bayesian demography 250 years after Bayes.
Bijak J; Bryant J
Popul Stud (Camb); 2016; 70(1):1-19. PubMed ID: 26902889
[TBL] [Abstract][Full Text] [Related]
47. Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?
O'Hagan A; Stevens JW
Health Econ; 2003 Jan; 12(1):33-49. PubMed ID: 12483759
[TBL] [Abstract][Full Text] [Related]
48. Bayesian variable selection in cost-effectiveness analysis.
Negrín MA; Vázquez-Polo FJ; Martel M; Moreno E; Girón FJ
Int J Environ Res Public Health; 2010 Apr; 7(4):1577-96. PubMed ID: 20617047
[TBL] [Abstract][Full Text] [Related]
49. Sample size determination for cost-effectiveness trials.
Willan AR
Pharmacoeconomics; 2011 Nov; 29(11):933-49. PubMed ID: 21988292
[TBL] [Abstract][Full Text] [Related]
50. Methods for Handling Unobserved Covariates in a Bayesian Update of a Cost-effectiveness Model.
Thorpe B; Carroll O; Sharples L
Med Decis Making; 2018 Feb; 38(2):150-162. PubMed ID: 29202637
[TBL] [Abstract][Full Text] [Related]
51. An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography.
Pertile P
Int J Health Care Finance Econ; 2009 Sep; 9(3):317-32. PubMed ID: 19152067
[TBL] [Abstract][Full Text] [Related]
52. Why Bayesian analysis hasn't caught on in healthcare decision making.
Winkler RL
Int J Technol Assess Health Care; 2001; 17(1):56-66. PubMed ID: 11329845
[TBL] [Abstract][Full Text] [Related]
53. Bayesian analysis: a new statistical paradigm for new technology.
Grunkemeier GL; Payne N
Ann Thorac Surg; 2002 Dec; 74(6):1901-8. PubMed ID: 12643371
[TBL] [Abstract][Full Text] [Related]
54. Bayesian methods for evidence synthesis in cost-effectiveness analysis.
Ades AE; Sculpher M; Sutton A; Abrams K; Cooper N; Welton N; Lu G
Pharmacoeconomics; 2006; 24(1):1-19. PubMed ID: 16445299
[TBL] [Abstract][Full Text] [Related]
55. [Bayesian inference in clinical reasoning].
Canals L M
Rev Med Chil; 2019 Feb; 147(2):231-237. PubMed ID: 31095172
[TBL] [Abstract][Full Text] [Related]
56. [Economic evaluations of health technologies: a global perspective for their implementation in Latin America].
Espinoza M; Castillo-Riquelme M; Zarate V
Rev Peru Med Exp Salud Publica; 2011; 28(3):535-9. PubMed ID: 22086637
[TBL] [Abstract][Full Text] [Related]
57. Bayesian Statistics for Surgical Decision Making.
Hatton GE; Pedroza C; Kao LS
Surg Infect (Larchmt); 2021 Aug; 22(6):620-625. PubMed ID: 33395554
[No Abstract] [Full Text] [Related]
58. Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions.
Fenwick E; O'Brien BJ; Briggs A
Health Econ; 2004 May; 13(5):405-15. PubMed ID: 15127421
[TBL] [Abstract][Full Text] [Related]
59. Before/after Bayes: A comparison of frequentist and Bayesian mixed-effects models in applied psychological research.
Flores RD; Sanders CA; Duan SX; Bishop-Chrzanowski BM; Oyler DL; Shim H; Clocksin HE; Miller AP; Merkle EC
Br J Psychol; 2022 Nov; 113(4):1164-1194. PubMed ID: 35906743
[TBL] [Abstract][Full Text] [Related]
60. Bayesian sample size determination for cost-effectiveness studies with censored data.
Beavers DP; Stamey JD
PLoS One; 2018; 13(1):e0190422. PubMed ID: 29304143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
